Gland Pharma Limited — Q3 FY25 earnings call

Call held 3 Feb 2025

Management summary

Gland Pharma delivered a resilient Q3 FY25, characterized by significant margin expansion in its base business despite a revenue decline in that segment. While the consolidated performance was bolstered by new launches and improved product mix, the Cenexi acquisition continues to face operational and regulatory headwinds, delaying its EBITDA breakeven target. Management is pivoting towards high-value biologics and CDMO opportunities to drive long-term growth.

Highlights

  • Consolidated Revenue stood at ₹1,384.1 crore (INR 13,841 million), with a consolidated EBITDA margin of 26%, up 300 bps YoY.

  • Base business (ex-Cenexi) EBITDA margin reached a robust 39%, compared to 34% in the same period last year.

  • Net Profit (PAT) increased by 7% YoY to ₹204.7 crore (INR 2,047 million), showing a 25% sequential growth.

  • Cenexi reported a negative EBITDA of ₹31.2 crore (INR 312 million) due to an unannounced regulatory inspection at the Fontenay site.

  • Launched 13 new molecules in the US market during the quarter, strengthening the product portfolio.

  • Received EIR from the US FDA for Dundigal and Pashamylaram facilities, signifying successful closure of inspections.

  • Signed a CDMO collaboration term sheet with Shanghai Henlius Biotech for biosimilar manufacturing.

Concerns

  • Regulatory Inspection Impact at Cenexi

Key financials

  1. Revenue ₹13,841 Mn
  2. EBITDA Margin 26%
  3. PAT ₹2,047 Mn +7%YoY
  4. R&D Spend ₹437 Mn -17.5%YoY
  5. Base Business EBITDA Margin 39%

What they filed

Q1 FY27: revenue up 23.9%, net profit up 35.3% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue1,063 1,011 1,030 1,039 1,074 +1%1,178 +17%1,262 +23%1,287 +24%
EBITDA364 391 394 359 375 +3%422 +8%508 +29%474 +32%
Net profit282 295 290 269 302 +7%308 +4%420 +45%364 +35%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

  • Base Business (ex-Cenexi)
    ₹10,123 Mn Revenue39% EBITDA Margin-8% Revenue Growth
  • Cenexi
    41 million eur Revenue₹-312 Mn EBITDA77% Gross Margin

Guidance & targets

Profitability

  • Cenexi EBITDA Breakeven Profitability · Q3 FY26 · Medium confidence Q3 FY26

    Previously Q4 FY25 → Q3 FY26

    Like we just mentioned that we expect now to EBITDA breakeven at Q3 FY '26 next year.

    — Ravi Mitra, CFO

Revenue

  • Cenexi Annual Revenue Threshold Revenue · FY26 · Medium confidence €200 million
    This will be driven by our efforts to push revenue beyond the EUR 200 million threshold.

    — Alain Kirchmeyer, CEO Cenexi

  • Biologics CDMO Revenue Generation Revenue · FY26 · High confidence Incremental revenue
    This is expected to generate incremental revenue starting next financial year.

    — Srinivas Sadu, Executive Chairperson

Capacity

  • Biologics Drug Substance Capacity Expansion Capacity · next few years · Medium confidence 15 KL
    So, we're already looking at expansion of the drug substance side to increase the capacity to 15 KL to meet the demand.

    — Srinivas Sadu, Executive Chairperson

Capex

  • GLP-1 Cartridge Capacity Investment Capex · 18 months · Medium confidence ₹200 crore
    Around I think INR200 crores... 18 months.

    — Srinivas Sadu, Executive Chairperson

Risks & concerns

  • Regulatory Inspection Impact at Cenexi

    high

    Unannounced ANSM inspection at Fontenay facility halted production for 3 weeks and requires corrective measures, delaying profitability.

    Management acknowledged

  • Dependency on Chinese API for Heparin

    medium

    Management admits continued dependence on China for Heparin API, though they view potential US tariffs on Chinese finished products as a competitive advantage.

    Both acknowledged

  • US Market Volume Volatility

    medium

    Analysts questioned the Q-o-Q decline in US run rate; management attributed it to shipping timing for Enoxaparin and Ketorolac.

    Analyst downplayed

Areas of evasion (2)

  • Specific details on the observations from the ANSM inspection at Cenexi.
  • Exact revenue numbers for the GLP-1 contracts.

Q&A highlights

3 direct
US Business Volume Decline Direct
It is just a shipping timing thing which instead of Q3, we will be probably planning for next quarter.

Clarifies that the 8% revenue drop in the base business was due to timing of shipments (Enoxaparin) rather than structural demand issues.

Asked by Bino Pathiparampil, Elara Capital

Cenexi Breakeven Delay Direct
So, we lost production during that time. And there are corrective measures which we need to take... That's why we're estimating now it could be the third quarter.

Explains the shift in Cenexi's profitability timeline from Q4 FY25 to Q3 FY26 due to a 3-week regulatory inspection and subsequent corrective actions.

Asked by Neha Manpuria, Bank of America

Biologics Capacity and Henlius Agreement Direct
No, an additional 15 KL capacity.

Reveals a significant scale-up in biologics manufacturing ambition, moving beyond the existing 8 KL capacity to support the new Henlius partnership.

Asked by Harsh Bhatia, Bandhan Mutual Fund

2 min read 5 chapters

Detailed narrative

Cenexi Regulatory Headwinds Delay Profitability

The Cenexi business recorded revenue of €41 million in Q3 FY25, which was below management's internal estimates. The primary driver for this miss was an unannounced inspection by the French Health Authority (ANSM) at the Fontenay facility, which disrupted manufacturing for approximately three weeks. Consequently, the timeline for EBITDA breakeven has been pushed back from Q4 FY25 to Q3 FY26. Management is now focused on pushing annual revenue beyond the €200 million threshold to achieve sustainable profitability.

Base Business Margin Resilience Amidst Volume Shifts

Gland's base business (excluding Cenexi) demonstrated strong operational efficiency, with EBITDA margins expanding to 39% from 34% YoY. This improvement occurred despite an 8% YoY revenue decline in the segment, which management attributed to shipping delays for key products like Enoxaparin and Ketorolac. The margin expansion was driven by a favorable product mix, including 13 new molecule launches in the US, and effective cost management measures.

Strategic Pivot to Biologics and CDMO

Management highlighted two major collaborations in the biologics space: a partnership with Dr. Reddy's Laboratories and a new non-binding term sheet with Shanghai Henlius Biotech. To support these initiatives, Gland is evaluating a significant capacity expansion of 15 KL in drug substance manufacturing, with an estimated capex of $80 million to $100 million. Incremental revenue from the Dr. Reddy's collaboration is expected to begin in FY26.

US Market Dynamics and Regulatory Clearance

The company received a major regulatory boost with the receipt of EIRs for its Dundigal and Pashamylaram facilities, successfully closing large-scale US FDA inspections. In the US market, Gland launched 27 molecules and 39 SKUs year-to-date, with new launches contributing approximately 5% of total revenue in Q3. Management remains aggressive in the US, targeting complex generics and RTU (Ready-to-Use) infusion bags to maintain high gross margins.

Geographic Diversification and RoW Strategy

Revenue from Rest of the World (RoW) markets increased to 21% of total revenues. Under the new CEO, Shyamakant Giri, Gland is shifting its RoW strategy from a 'continent lens' to focusing on top-tier high-value countries like Saudi Arabia, Mexico, and South Africa. While a Saudi tender shipment was delayed this quarter, management expects allotment to hospitals to resume in Q4 FY25 or early FY26.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls